Taiwan pauses second doses of Pfizer-BioNTech COVID-19 vaccine for older children due to myocarditis

Michael Walter | | Cardiovascular Business | COVID-19
vaccine

In Taiwan, second doses of the Pfizer-BioNTech COVID-19 vaccine are being temporarily suspended for children between the ages of 12 and 17 due to concerns over the risk of myocarditis.

Chen Shih-chung, the head of Taiwan’s Central Epidemic Command Center, announced the news on Nov. 10. A final decision, he said, is expected in two weeks.

A new report from Taiwan’s Central News Agency detailed the ongoing situation. So far, the website reported, 1.1 million people between the ages of 12 and 17 have received their first dose of the Pfizer-BioNTech vaccine in Taiwan. Of that group, there have been 17 reported cases of myocarditis or pericarditis. Fourteen of those cases were seen in male patients.

Three additional cases of myocarditis or pericarditis were reported in men between the ages of 18 and 21, bringing the grand total to 20 cases. While 18 of those patients have already been discharged from the hospital, one is still currently hospitalized and another was never hospitalized.

Click the link below for the full story:

Second Pfizer-BNT dose for 12-17 age group to be decided in two weeks

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

AHA issues a scientific statement on COVID-19 cardiac arrhythmias
History of COVID-19 doubles long-term risk of heart attack, stroke or death
Monitoring acute heart patients at home linked to considerable cost savings
A key update on how COVID-19 caused dangerous MIS-C inflammation in children
Q&A: Cardiologist Karen Joynt Maddox on why new healthcare policies are not improving outcomes
COVID-19 vaccines helped heart failure patients stay out of the hospital and live longer

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."